Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03673124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ribociclib and Letrozole Treatment in Ovarian Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Dec 23, 2025
    • Start date: Dec 14, 2018 to May 20, 2019
    v22
  2. Primary endpoint revised
    • Secondary endpoints revised (4)
    v21
  3. Primary completion date changed from estimate of Dec 31, 2023 to Dec 23, 2024
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    • Eligibility criteria expanded, about 8 words
    v20
  4. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Aug 31, 2023 to Dec 31, 2023
    • Site details revised at 27 of 27 sites
    v19
  5. Primary completion date: Dec 31, 2021 to Aug 31, 2023
    • Study completion date: Dec 31, 2021 to Dec 31, 2024
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Study sites: 26 to 27v17
  2. Re-verified, no change to tracked fieldsv16
  3. Study sites: 25 to 26v15
  4. Primary completion date: Jul 30, 2020 to Dec 31, 2021
    • Study sites: 22 to 25
    • Study completion date: Jul 30, 2021 to Dec 31, 2021
    v14
  5. Study sites: 21 to 22v13
  6. Site contacts updated at 1 of 21 sitesv12
  7. Study sites: 20 to 21v11
  8. Study sites: 19 to 20v10
  9. Study sites: 18 to 19v9
  10. Study sites: 15 to 18
    • Eligibility criteria expanded, about 47 words
    v8
  11. Study sites: 14 to 15v7
  12. Study sites: 13 to 14v6
  13. Study sites: 11 to 13v5
  14. Study sites: 9 to 11v4
  15. Study sites: 1 to 9
    • Eligibility criteria revised
    v3
  16. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 30, 2018 to Dec 14, 2018
    • Eligibility criteria expanded, about 585 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
Trial Details
NCT Number NCT03673124
Lead Sponsor Gynecologic Oncology Group
Collaborators: Novartis
Conditions
(from sponsor)		 Low Grade Serous Carcinoma
Related terms Cystadenocarcinoma, Serous
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov